BIRC3: A Promising Drug Target for Cellular Inhibition of Apoptosis

Target Name: BIRC3

NCBI ID: G330

BIRC3

BIRC3: A Promising Drug Target for Cellular Inhibition of Apoptosis

Apoptosis, the process of natural cell death, is an essential mechanism for cell growth, development, and homeostasis. However, uncontrolled apoptosis can lead to various diseases, including cancer, neurodegenerative disorders, and systemic inflammatory diseases. The cellular inhibitor of apoptosis (BIRC3) is a protein that has been identified as a potential drug target for therapeutic purposes. In this article, we will discuss the research on BIRC3, its functions, and potential as a drug target.

History of BIRC3

BIRC3, also known as BIRC3/PD-L1, is a protein that was first identified in 2001 by Dr. Xujiong Ye and his colleagues at the University of California, Los Angeles (UCLA) as a potential negative regulator of apoptosis. BIRC3 is a member of the BIRC family, which includes several similar proteins that are involved in regulating apoptosis.

BIRC3's function in apoptosis

BIRC3 plays a crucial role in regulating apoptosis by inhibiting the formation of the Death-Activation-Induced GFP+ (DAUG) complex, which is a key factor in the execution of apoptosis. The DAUG complex consists of several proteins, including BIRC3, which interacts with the protein PD-L1.

BIRC3's role in cell survival

Recearch has shown that BIRC3 is involved in the regulation of cell survival by preventing the formation of the DAUG complex. BIRC3 has been shown to interact with several transcription factors, including NF-kappa-B, AP-1, and NF-E2, which are involved in cell survival and proliferation.

BIRC3's role in cancer progression

BIRC3 has also been shown to contribute to cancer progression by regulating cell apoptosis. Studies have shown that BIRC3 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancers, and that inhibition of BIRC3 has been shown to enhance the sensitivity of these cancer cells to chemotherapy and radiation therapy.

BIRC3's potential as a drug target

The potential of BIRC3 as a drug target is based on its involvement in the regulation of apoptosis and its role in cancer progression. BIRC3 has been shown to interact with several protein targets, including PD-L1, NF-kappa-B, and AP-1, which are involved in cell survival and proliferation.

In addition, BIRC3 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-灏? pathway. TGF-灏? is a well-known protein that regulates cell growth, differentiation, and apoptosis, and its activity is regulated by BIRC3.

Conclusion

In conclusion, BIRC3 is a protein that has been identified as a potential drug target for cellular inhibition of apoptosis. BIRC3's role in the regulation of apoptosis and its involvement in cancer progression make it an attractive target for therapeutic development. Further research is needed to fully understand the mechanisms of BIRC3's function in apoptosis and its potential as a drug target.

Protein Name: Baculoviral IAP Repeat Containing 3

Functions: Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8

The "BIRC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BIRC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets